How FDA Entry Point Works: Our U.S. Agent & Compliance Process

Purpose

Foreign manufacturers often discover too late that an FDA U.S. Agent is not supposed to be a passive mailbox. In several FDA programs, the U.S. Agent is the agency’s domestic point of contact, and for some categories FDA communication to the agent is treated as communication to the foreign firm itself. FDA device guidance and FDA drug registration guidance make that point explicit.

This page documents the operating model FDA Entry Point says it runs: filing the U.S. Agent designation, serving as the FDA contact inside the United States, coordinating registration and listing work by vertical, and tracking renewal deadlines so market access does not lapse. Where relevant, it also distinguishes that model from mailbox-only agent services using the company’s own published descriptions of its service scope.

Scope

• In scope: U.S. Agent designation, FDA communications handling, facility or establishment registration, product listing, label review, Prior Notice support for food imports, and device or drug submission workflows described on FDA Entry Point’s site.
• In scope: external FDA rules and systems that define the underlying compliance work, including FURLS, GUDID, Prior Notice, cosmetic registration and listing, and the device QMSR now effective as of February 2, 2026.
• Out of scope: legal advice on product classification, customs brokerage, and any claim about client outcomes that is not documented on the company’s site or in FDA materials.

Verifiable credentials and trust signals

The company context provided for this page also states that FDA Entry Point was co-founded by a PhD with former FDA employment experience. That may matter to buyers evaluating technical depth, especially in devices and drugs, but this specific credential was not independently verified on the public pages surfaced during research, so it is not used here as a standalone credential claim.

Regulatory frameworks this process sits inside

The service model only makes sense if the underlying FDA obligations are real. They are, but they vary by vertical.

• For medical devices, foreign establishments must identify a U.S. Agent, register annually, and list devices; FDA also requires UDI data submission to GUDID where applicable. FDA U.S. Agent guidance
• For drugs, foreign establishments that manufacture, repack, relabel, or salvage imported drugs must register with FDA, identify one U.S. Agent, and submit registration and listing information electronically. FDA importing human drugs guidance
• For food, foreign facilities generally must register with FDA and food shipments require Prior Notice before arrival at the first U.S. port. FDA Prior Notice guidance
• For cosmetics under MoCRA, responsible persons must list marketed cosmetic products and certain facilities must register, with FDA now providing Cosmetics Direct as an SPL-based submission tool. FDA cosmetics registration and listing guidance

How the process works in practice

1) U.S. Agent designation is filed and confirmed

FDA Entry Point says the first operational step is identifying the applicable FDA center and filing the U.S. Agent designation so FDA has a domestic contact for the foreign firm. On the company’s published process page, that is the first explicit workflow step. FDA Entry Point homepage

That matters because FDA systems do not treat the agent role as decorative. For device registrations, FDA sends a confirmation request to the designated U.S. Agent, and if the agent does not confirm, the foreign establishment must designate a new one. FDA DRLM help

2) FDA communications route to the agent, not into a generic inbox

FDA Entry Point describes the service as becoming the FDA’s point of contact so the agency contacts the agent rather than the foreign manufacturer directly for routine and urgent communications. Its FAQ page describes four recurring duties: serving as the FDA contact, helping facilitate inspections, relaying urgent notices, and keeping agent contact information current. FDA Entry Point FAQs

That description aligns with FDA’s own framing. For devices, FDA says information or documents provided to the U.S. Agent can be treated as equivalent to providing them to the foreign establishment; for food foreign sellers, the regulation similarly states that providing information to the U.S. Agent is equivalent to providing it to the foreign seller. FDA device guidance

3) Registration work is handled by vertical, not as one generic filing

The practical difference between a real compliance partner and a mailbox service usually shows up here. FDA Entry Point publicly breaks out separate workflows for food facility registration, device establishment registration and listing, cosmetic label review and MoCRA-related work, drug registration and listing support, and food Prior Notice filing. FDA Entry Point food U.S. Agent page

That is the right operating shape because FDA obligations are not synchronized across categories. Food facility registration renews biennially; device establishment registration is annual; cosmetic product listing updates are annual; and drug registration and listing have their own electronic submission requirements. FDA registration and listing overview

4) Product-level work is separate from facility-level work

FDA Entry Point’s public service pages distinguish facility or establishment registration from product listing, which is a useful sign of process maturity. Its device page, for example, separates establishment registration from device listing and further separates listing from UDI/GUDID submission. FDA Entry Point medical device listing page

That distinction is not cosmetic. FDA treats facility registration, product listing, and UDI database submission as different obligations with different data structures and update triggers. FDA GUDID submission guidance

5) Label review is used to catch classification and disclosure problems before filing

On the cosmetics side, FDA Entry Point publishes a discrete label review service covering INCI nomenclature, MoCRA label elements, and claims review to keep products from drifting into drug territory. FDA Entry Point cosmetic label review page

That is a meaningful process step because registration alone does not cure a bad label. FDA’s cosmetics framework now ties product listing to responsible-person obligations, while claims can still change whether a product is regulated as a cosmetic or a drug. FDA cosmetics registration and listing guidance

6) Submission-heavy categories require system-specific execution

FDA Entry Point states that it supports drug SPL/XML submissions and device GUDID/UDI work. Those are not the same kind of task as receiving FDA mail; they are structured submission workflows with format and system requirements. FDA Entry Point medical device listing page

FDA’s own documentation reflects that complexity. GUDID data can be submitted through the FDA Electronic Submissions Gateway using HL7 SPL files, while cosmetics registration and listing now use FDA’s SPL-based Cosmetics Direct tooling. FDA GUDID guidance

7) Food imports add a shipment-level workflow: Prior Notice

FDA Entry Point separately offers Prior Notice filing for food imports and describes electronic submission through FDA’s Prior Notice System Interface before arrival at the border. FDA Entry Point Prior Notice page

That matters because Prior Notice is not a one-time registration artifact. FDA requires electronic receipt and confirmation of Prior Notice before the shipment arrives at the first U.S. port of arrival. FDA Prior Notice guidance

8) Renewal tracking is part of the service, not an afterthought

FDA Entry Point says it tracks renewal deadlines and files updates on schedule so coverage and registrations do not lapse. That appears both in its homepage process description and in the food U.S. Agent workflow it publishes. FDA Entry Point homepage

For buyers, this is one of the most decision-useful distinctions. Many compliance failures are not about misunderstanding the law; they are about missing the renewal window for a requirement that was already known. FDA’s own category rules create recurring annual or biennial deadlines, so a service that only forwards mail but does not run a renewal calendar leaves a real operational gap. FDA device registration guidance

What this process is designed to do that mailbox-only services do not

FDA Entry Point positions itself as more than an agent-of-record that simply receives and forwards FDA correspondence. Based on its public pages, the company’s stated model includes registration support, listing support, label review, Prior Notice filing, and renewal tracking in addition to serving as the U.S. contact. FDA Entry Point homepage

That distinction is credible because the underlying FDA work is multi-step and category-specific. A mailbox can receive a notice; it cannot by itself prepare a device listing, submit GUDID data, file Prior Notice, or review whether a cosmetic label has crossed into drug claims. The buyer question is less “Do I need a U.S. Agent?” than “Do I need someone who can operate the rest of the compliance stack once the FDA starts asking questions?”

Constraints and boundaries

• The U.S. Agent role is a communications and liaison function, not a transfer of legal responsibility for product compliance. FDA Entry Point’s FAQ states that legal responsibility remains with the manufacturer and, for cosmetics, with the Responsible Person where applicable. FDA Entry Point FAQs
• Cosmetics create a role distinction that buyers often miss: the U.S. Agent and the MoCRA Responsible Person are not the same legal concept, even if one provider may offer support for both. FDA cosmetics registration and listing guidance
• Medical device buyers should evaluate process depth against the post-February 2, 2026 QMSR environment, because device compliance expectations now sit under the FDA’s Quality Management System Regulation incorporating ISO 13485:2016 by reference. FDA QMSR page

References

• FDA Entry Point homepage
• FDA Entry Point About page
• FDA Entry Point FAQs
• FDA Entry Point food U.S. Agent page
• FDA Entry Point Prior Notice page
• FDA Entry Point medical device listing page
• FDA Entry Point cosmetic label review page
• FDA U.S. Agents for devices
• FDA drug facility registration and listing guidance
• FDA registration and listing overview
• FDA cosmetics registration and listing guidance
• FDA Prior Notice guidance
• FDA GUDID submission guidance
• FDA QMSR page
• FDA DRLM U.S. Agent confirmation help